점액세균 Myxococcus stipitatus KYC4013에 의한 생리활성물질생산
Production of Bioactive Substances by a Myxobacterium Myxococcus stipitatus KYC4013
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Myxococcus stipitatus KYC4013 extract exhibited the most potent antifungal activity among the extracts of 207 Myxococcus strains isolated in Korea. High-resolution LC-MS analysis revealed that M. stipitatus KYC4013 produces five antifungal substances and three other secondary metabolites that were predicted to be melithiazol and phenalamide derivatives, respectively. The putative melithiazol derivatives were best produced in CYS medium and the putative phenalamide derivatives were best produced in VY3 medium.
Abstract
Myxococcus stipitatus KYC4013 extract exhibited the most potent antifungal activity among the extracts of 207 Myxococcus strains isolated in Korea. High-resolution LC-MS analysis revealed that M. stipitatus KYC4013 produces five antifungal substances and three other secondary metabolites that were predicted to be melithiazol and phenalamide derivatives, respectively. The putative melithiazol derivatives were best produced in CYS medium and the putative phenalamide derivatives were best produced in VY3 medium.
참고문헌 (20)
- 안종웅, "점액세균Myxococcus sp. JW154로 부터 항균물질의 분리 및 식물병원균에 대한 in vivo 활성", 한국미생물·생명공학회지, 30(2), pp.162~166 (2002), 한국미생물·생명공학회
- 안종웅, "Myxococcus stipitatus JW117이 생산하는 Polyene계 세포독성 물질의 분리 및 특성", 한국미생물·생명공학회지, 30(2), pp.157~161 (2002), 한국미생물·생명공학회
- Garcia R, "Expanded phylogeny of myxobacteria and evidence for cultivation of the ‘unculturables’", Mol. Phylogenet. Evol, 57, pp.878~887 (2010)
- Gerth K, "Myxobacteria: proficient producers of novel natural products with carious biological activities-past and future biotechnological aspects with the focus on the genus Sorangium", J. Biotech, 106, pp.233~253 (2003)
- Huntley S, "Complete genome sequence of Myxococcus stipitatus strain DSM 14675, a fruiting myxobacterium", Genome Announc, 1, pp.e0010013~ (2013)
- Kim YJ, "Isolation and structural elucidation of stipiamide, a new antibiotic effective to multidrug-resistant cancer cells", J. Antibiot, 44, pp.553~556 (1991)
- 김용석, "Myxobacteria의 생리활성 물질", 한국미생물·생명공학회지, 31(1), pp.1~12 (2003), 한국미생물·생명공학회
- Li Z-F, "Genome sequence of the halotolerant marine bacterium Myxococcus fulvus HW-1", J. Bacteriol, 193, pp.5015~5016 (2011)
- Reichenbach H, "Bergey’s Manual of systematic Bacteriology", pp.1059~1144 (2005), Bergey’s Manual Trust
- Reichenbach H, "Drug Discovery from Nature", pp.149~179 (1999), Springer Verlag
- Reichenbach H, "The Prokaryotes", pp.3416~3487 (1992), Springer Verlag
- Sasse F, "Melithiazols, new beta-methoxyacry-late inhibitors of the respiratory chain isolated from myxobacteria. Production, isolation, physico-chemical and biological properties", J. Antibiot, 52, pp.721~729 (1999)
- Shi W, "Motility and chemotaxis in Myxococcus xanthus", Methods Mol. Genet, 3, pp.258~269 (1994)
- 신혜진, "Corallococcus와 Myxococcus 속 점액세균 균주들에 의한 항균 물질의 생산", 한국미생물·생명공학회지, 41(1), pp.44~51 (2013), 한국미생물·생명공학회[DOI]
- Trowitzsch-Kienast W, "Antibiotika aus gleitenden bakterien, 45. Phenalamide, neue HIV-1-inhibitoren aus Myxococcus stipitatus Mx s40", Liebigs Annalen der Chemie, 1992, pp.659~779 (1992)
- Weinig S, "Melithiazol biosynthesis: further insights into myxobacterial PKS", NRPS systems and evidence for a new subclass of methyl transferases, 2003, pp.10, 939~952
- Weissman KJ, "A brief tour of myxobacterial secondary metabolism", Bioorg. Med. Chem, 17, pp.2121~2136 (2009)
- Weissman KJ, "Myxobacterial secondary metabolites: bioactivities and modes-of-action", Nat. Prod. Rep, 27, pp.1276~1295 (2010)
- Wenzel SC, "The impact of genomics on the exploitation of the myxobacterial secondary metabolome", Nat. Prod. Rep, 26, pp.1385~1407 (2009)
- Zusman DR, "Chemosensory pathways, motility and development in Myxococcus xanthus", Nat. Rev. Microbiol, 5, pp.862~872 (2007)